Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNFα-antagonists;Die therapie der ankylosierenden spondylitis und der undifferenzierten spondyloarthritis mit TNFα-antagonisten

Zeitschrift fur Rheumatologie

Volumn 62, Issue 3, 2003, Pages 218-227

  Brandt, Jan ^b   Sieper, Jochen ^b   Braun, Jürgen ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Ankylosing spondylitis; Etanercept; Infliximab; TNF antagonists; Undifferentiated spondyloarthritis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW TOXICITY; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEMYELINATING DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG INFUSION; DRUG MONITORING; DUAL ENERGY X RAY ABSORPTIOMETRY; HEART FAILURE; HUMAN; INFECTIOUS COMPLICATION; INFLAMMATORY DISEASE; INJECTION SITE; LYMPHOMA; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; SEPSIS; SIDE EFFECT; SPONDYLOARTHROPATHY; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0038302443     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-003-0518-7     Document Type: Article

References (59)

1. Allali F, Breban M, Porche R, Maillefert J F, Dougados M, Roux C (2003) Increase of bone mineral density of patients with spondyloarthropathy treated with anti-tumor necrosis factor α. Ann Rheum Dis 62:347-350
2. Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge Clin Exp Rheumatol 20:S152-157
3. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47:506-512
4. Bollow M, Fischer T, Reißhauer H, Sieper J, Hamm B, Braun J (2000) T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Ann Rheum Dis 59:135-140
5. Boonen A, Chorus A, Miederna H, van der Heijde D, van der Tempel H, van der Linden S (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60:353-358
6. Brandt J, Bollow M, Haberle J, Rudwaleit M, Eggens U, Distler A et al (1999) Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloar thropathy. Rheumatology 38:831-836
7. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346-1352
8. Brandt J, Haibel H, Reddig J, Sieper J, Braun J (2002) Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor α monoclonal antibody infliximab. J Rheumatol 29:118-122
9. Brandt J, Haibel H, Reddig J, Sieper J, Braun J (2001) Treatment of patients with severe ankylosing spondylitis with infliximab - a one year follow up (2001) Arthritis Rheum 44:2936-2937
10. Brandt J, Kariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Sieper J, Braun J (2003) Six months results of a double-blind placebo controlled clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum (in press)
11. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, van der Heijde D (2003) MRI examinations of the spine in patients with ankylosing spondylitis (AS) before and after infliximab therapy after evaluation of a new scoring system. Arthritis Rheum (in press)
12. Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J (1994) Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 37:1039-1045
13. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499-505
14. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A et al (1998) Prevalence of spondylarthropathies in HLA B27-positive and -negative blood donors. Arthritis Rheum 41:58-67
15. Braun J, Bollow M, Sieper J (1998) Radiology and pathology of the spondyloarthropathies. Rheum Dis Clin N Am 24:697-735
16. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab - a double-blind placebo controlled multicenter trial. Lancet, 359:1187-1193
17. Braun J, Sieper J (1996) The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 8:275-287
18. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, Euller-Ziegler L, Sibilia J, Perdriger A, Mezieres M, Alexandre C, Dougados M (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 41:1280-1285
19. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842-1847
20. Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veterans affairs cooperative study. Arthritis Rheum 42:2325-2329
21. D'Agostino MA, Breban M, Said-Nahal R, Dougados M (2002) Refractory inflammatory heel pain in spondyloarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum 46:840-841
22. Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP (2002) Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study. Gastroenterol Clin Biol 26:973-979
23. Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, Zeidler H et al (2001) Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 44:180-185
24. Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H et al (1999) Ankylosing spondylitis: what is the optimum duration of a clinical study? a one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 38:235-244
25. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al (1991) The european spondyloarthropathy study group preliminary criteria of the classification of spondyloarthropathy. Arthritis Rheum 34:1218-1272
26. Collantes E, Munoz-Villanueva MC, Sanmarti R, Canete JD, Gratacos J, Zarco P, Gonzalez C, Torre-Alonso JC (2003) Infliximab in refractory spondyloarthropathies, preliminary results in a Spanish population. Ann Rheum Dis (in press)
27. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110
28. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681-1690
29. Francois RJ, Gardner DL, Degrave EJ, Bywaters EG (2000) Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 43:2011-2024
30. Garrett S, Jenkinson TR, Kennedy LG, Whitelock HC, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis. The Bath AS disease activity index. J Rheumatol 21:2286-2291
31. Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346:1349-1356
32. Gran JT, Husby G, Hordvik M (1985) Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 44:359-367
33. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541-1548
34. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
35. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM (2002) Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 61:207-212
36. Laloux L, Voisin MC, Allain J, Martin N, Kerboul L, Chevalier X, Audepierre P (2001) Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 60:316-321
37. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, Luongo R, Russell AS (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29:959-965
38. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P (2001) Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 44:2112-2117
39. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P (2003) Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 62:74-76
40. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, Deicher H (1988) Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 15:1109-1114
41. McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P (1998) Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. 41:694-700
42. Meador R, Hsia E, Kitumnuaypong T, Schumacher HR (2002) TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin Exp Rheumatol 20:S130-134
43. Mease PJ, Goffe BS, Metz J, Vander-Stoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385-390
44. Mielants H, Veys EM (1985) HLA B27-related arthritis and bowel inflammation: sulfasalazine in HLA B27-related arthritis. J Rheumatol 12:287-293
45. Muche B, Bollow M, François RJ, Sieper J, Hamm B, Braun J (2003) Which anatomical structures are involved in early and late sacroiliitis in spondyloarthritis - a detailed analysis by contrast enhanced magnetic resonance imaging. Arthritis Rheum (in press)
46. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Lueftl M (2001) Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144:587-589
47. Sampaio-Barros PD, Bertolo MB, Kraemer MH, Marques-Neto JF, Samara AM (2001) Undifferentiated spondyloarthropathies: a 2-year follow-up study (2001) Clin Rheumatol 20:201-206
48. Sandborn WJ (1999) Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 5:119-133
49. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088-1094
50. Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A et al (1999) Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. J Rheumatol 26:2622-2627
51. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R (2001) Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 28:1605-1614
52. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59:428-433
53. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2002) Savety and efficacy of a retreatment regiment of 10 mg/kg infliximab every 14 weeks in patients with active spondylarthropathy. Arthritis Rheum 46:S430
54. Van den Bosch F, Kruithof E, Baeten D, Herseens A, De Keyser F, Mielants H, Veys EM (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 46:755-765
55. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H (2000) Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356:1821-1822
56. Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
57. van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M, Falkenbach A, Genth E, The HG, van der Linden S (2001) Combined Spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 45:430-438
58. Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12:247-255
59. Zink A, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27:613-622